A recent study suggests that individuals who discontinue new GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who end conventional diet and exercise plans.
Published data in a prominent health publication shows that while obese individuals often shed about a fifth of their total mass while on the medication, the weight returns at an estimated rate of nearly a kilo each month once they quit.
"Individuals purchasing these medications need to be informed of the risk of rapid rebound weight gain when the treatment is stopped," stated expert Dr. Susan Jebb.
Such speed of recovery suggests a return to pre-treatment weight in about one and a half years.
Weighing Therapies
The research, which examined 37 of trials involving over 9,000 of participants, contrasted the outcomes of GLP-1 agonists with older methods.
Scientists note that people who shed pounds through diet and exercise typically see a slower weight regain—approximately 100 grams monthly—post-intervention.
Explaining the Quick Regain
Doctors believe the way of the injections explains the heightened regain.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Long-term administration of the hormone concentrations several times higher than the body's typical production may cause the body to produce less of its own natural hormone, and may also lessen responsiveness to its actions," explained Dr. Adam Collins, a nutrition expert.
"Discontinuation of this medication results in hunger is no longer kept in check, making binge eating far more likely."
An Ongoing Condition?
Health authorities recommend the jabs for people with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
Professionals say that, due to the high risk of relapse, the treatment should be considered long-term.
This view is supported by pharmaceutical companies, who note that the findings "underscore the long-term nature of excess weight," akin to managing conditions like hypertension.
User Experiences
People who have stopped the medication report a powerful resurgence of appetite.
"It felt as if a trigger flipping and you become ravenous," described a patient.
This difficulty is worsened if users have not developed lasting lifestyle or habit changes during treatment.
Widespread Use
Survey data suggest that millions of people in the UK have used these injections in the past year, with interest remaining high.
- Adoption is more common among females compared to males.
- The 40s and 50s age group shows the greatest usage rates.
- Many access the drugs through private healthcare rather than the NHS.
Ultimately, researchers stress that while these medications are potent tools for weight loss, they are not a permanent cure and long-term success relies on ongoing behavioural changes.
